CART123 Cells

Phase 1Biologic

UUniversity of Pennsylvania

CART123 Cells is one of 12 biologic programs targeting Relapsed/Refractory AML. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Relapsed/refractory AMLActive, not recruiting

Relapsed/refractory AMLPhase 1

Active, not recruiting

Competition

Competitive Landscape

15 competitors in Relapsed/refractory AML

#DrugCompanyPhaseTrials

Cytosar

Teva

Approved

5 2

Venclexta

AbbVie

Approved

3 3

Leustatin

EMD Serono

Approved

2 4

Dacogen

Sun Pharmaceutical Industries, Inc.

Phase 2

1 5

G-CSF

AArog Pharmaceuticals, Inc.

Phase 3

1 6

Vidaza

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 2

1 7

Luye

Ascentage Pharma Group Inc.

Phase 2

1 8

Jakafi

Incyte

Phase 1

1 9

Lisaftoclax

Ascentage Pharma Group Inc.

Phase 2

1 10

CART123 Cells

UUniversity of Pennsylvania

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2045

Phase 1Active, not recruiting

Relapsed/refractory AML

NCT06768476

Clinical

Trials by Indication[1]

Relapsed/Refractory AML1 trial

CART123 + Ruxolitinib in Relapsed/Refractory AML

Active, not recruiting·UUniversity of Pennsylvania·Phase 1·NCT06768476·12 enrolled

Pediatric1 trial

CD123 Redirected T Cells for AML in Pediatric Subjects

Terminated·UUniversity of Pennsylvania·Phase 1·NCT04678336·12 enrolled

Acute Myeloid Leukemia, in Relapse1 trial

Phase 1 Study of Lentivirally Transduced T Cells Engineered to Contain Anti-CD123 Linked to TCRζ and 4-1BB Signaling Domains in Subjects With Refractory or Relapsed Acute Myeloid Leukemia

Terminated·UUniversity of Pennsylvania·Phase 1·NCT03766126·22 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for CART123 Cells. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CART123 Cells compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CART123 Cells. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Pennsylvania company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: UUniversity of Pennsylvania

CART123 Cells

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2045

Trials by Indication[1]

Relapsed/Refractory AML1 trial

Pediatric1 trial

Acute Myeloid Leukemia, in Relapse1 trial

References

Drug Info

Quick Facts

Related News